Researchers at the University of Florida have identified a potential link between glucosamine use and accelerated progression of mild cognitive impairment to dementia, raising concerns for individuals taking this widely used joint supplement.
The study, published in Nature Metabolism, analyzed patient health records and examined brain tissue samples from mice and humans. While preliminary, the findings suggest a connection between glucosamine and worsening cognitive symptoms in those already experiencing mild cognitive impairment.
Mild cognitive impairment, or MCI, characterizes noticeable but not yet disabling memory or thinking issues beyond normal age-related changes. The research team found that glucosamine use correlated with a 25% increased likelihood of MCI progressing to dementia, and a similar increase in mortality risk among Alzheimer’s patients already diagnosed with dementia.
“This association doesn’t prove causation, but the consistency across human records and animal models demands closer clinical scrutiny,” noted senior researcher Dr. Ramon Sun. The team used AI to analyze UF Health records from 2012 to 2024, focusing on 1,896 Alzheimer’s patients and 2,750 with MCI who reported glucosamine use.
Central to the findings is a metabolic pathway involving protein sugar modifications, which appeared overactive in Alzheimer’s cases. Experiments showed that glucosamine amplified this process in both mice and human brain tissue, potentially disrupting critical cellular functions. When researchers blocked this sugar-tagging in mice, memory deficits improved, suggesting the pathway drives rather than merely accompanies the disease.
“Proteins require precise sugar tags to function properly,” explained co-author Dr. Matt Gentry. “Our results indicate Alzheimer’s brains produce too many tags, and this could be a therapeutic target beyond the traditional focus on plaques and tangles.”
While the study signals a need for caution among supplement users with cognitive concerns, it does not recommend discontinuing glucosamine without further evidence. Controlled clinical trials are necessary to confirm whether the supplement directly accelerates disease progression and identify vulnerable populations.
Glucosamine, derived from shellfish or corn, crosses the blood-brain barrier and enters pathways that modify proteins with sugar structures. In healthy brains, this process is normal, but Alzheimer’s-affected tissue showed excessive tagging. Mouse studies confirmed that blocking this mechanism improved social memory-related behaviors, reinforcing its potential role in cognitive decline.
The research underscores metabolism’s understudied role in neurodegeneration. As Dr. Sun states, addressing metabolic dysfunction could complement therapies targeting amyloid plaques and tau tangles, long the focus of Alzheimer’s research.
